FDA panel recommends drug strictly for African-Americans

Share this article:
The FDA moved one step closer to approving the first drug marketed to a specific ethnic group yesterday when an agency panel recommended that NitroMed's BiDil be marketed for strictly treating black people with heart failure.
The drug has  raised questions about how marketing, regulatory and political considerations play a role in new drug development, with critics of NitroMed saying the company has managed the regulatory system and patent law, along with historical inequities to drive its product to market.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.